QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets, today announced the authorization of its clinical trial application (CTA) by Health Canada for QRL-201, a first-in-class STATHMIN-2 (STMN2) precision medicine for ALS.
GoSecure, a leading provider of managed detection and response solutions and expert advisory services, today announced a new partnership with Check Point that will enable GoSecure to add support for Check Point’s security products, expanding their open ecosystem of MDR/XDR technology partners.
BioNova Receives Investigational New Drug Clearance for BN301 for the Treatment of Hematologic Malignancies in China
BioNova today announced that the Center of Drug Evaluation (CDE) of National Medical Products Administration (NMPA) had approved its investigational new drug (IND) application for BN301 (STRO-001) to conduct clinical trials in patients with hematologic malignancies in China.
Cipia (TASE:CPIA), a computer vision AI in-cabin automotive solutions provider, today announced an expansion of the company’s existing partnership with Ambarella, Inc. (NASDAQ: AMBA), an edge AI semiconductor and software company.
RallyBio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company, today announced that it has obtained worldwide exclusive rights to Sanofi’s KY1066, a preclinical potentially first-in-class antibody.